A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

AdaCore’s QGen Automated Code Generator Helps Develop New Artificial Lung Equipment to Treat Covid Patients in Only6 Months

Leading provider of software development and verification tools, AdaCore, has joined forces with the Eldorado Institute in Brazil and medical device manufacturer Braile Biomédica to help in the fight against COVID-19.

AdaCore’s code generation and model verification tool software suite, QGen, played an integral part in the development of Braile Biomédica’s new extracorporeal membrane oxygenation (ECMO) device to help COVID-19 sufferers experiencing blood oxygen deficits. Thanks to the technical expertise and dedication of all three organizations, what would have been a two-year development program has been completed in just six months.

AdaCore’s QGen is a qualifiable and tunable code generator for a safe subset of Simulink® and Stateflow® models. The Eldorado Institute had already used the software suite in a cardiac pacemaker pilot project. After using the pilot project to build up a mature understanding of how to use QGen in code generation and verification, they began applying QGen on other projects, including Braile Biomédica’s expedited ECMO device.

The Eldorado Institute (Eldorado) is a private research and technology organization (RTO) based in Brazil. It collaborates with technology companies around Brazil and in other countries to develop new products. Braile Biomédica initially partnered with Eldorado to develop hyperthermic intraperitoneal chemotherapy (HIPEC) equipment. Also known as “hot chemotherapy,” HIPEC is performed after tumors or lesions are removed from the abdominal area.

When the COVID-19 pandemic exploded in Brazil in March 2020, Braile Biomédica redeployed this technology into an ECMO device, designed to help patients battling the virus. The device supports patients with severe lung injuries, keeping the patient alive until the lung recovers and the disease regresses. It consists of a machine and a set of disposable devices, which together perform the circulation and oxygenation of the patient’s blood outside his or her body. QGen is an integral part of the process, delivering clean, readable code and ensuring accurate testing to ensure a high level of reliability and quality performance for the entire time the ECMO is in use.

The ECMO device had to be extremely reliable, regardless of the tight development timeframe. Treatments could last as long as thirty-forty days, during which time the ECMO is responsible for keeping the patient alive. High reliability in such a device is critical to patient survival. The easiest way to assure that is by using model-based systems engineering (MBSE) techniques to design and test the system, and then to generate the code for the target controller hardware directly from the model using an automated code generator, as provided by QGen.

AdaCore QGen Team Lead, JC Bernedo, says: “QGen is a trusted code generator, meaning that the source code it generates is guaranteed to be equivalent to the Simulink simulation environment and therefore directly usable without further manual review. This allows developers of critical systems to streamline their development, testing, and verification processes while providing additional safety guarantees to their customers. We are proud to have helped Braile Biomédica and The Eldorado Institute expedite the development of their life-saving ECMO device.”

Guilherme Fonseca, Manager of Research and Development at The Eldorado Institute adds: “When we were looking for a solution to our design testing and code generation requirements, we found that QGen best matched what we needed. It provided us with the best overall value, thanks to the easily readable generated code, and the guarantee of equivalence of behavior between the generated code and simulation. AdaCore showed us excellent partnership and support throughout the development process. Going forward, whenever we have an opportunity that demands development of high-risk, high-reliability software, we are going to use QGen to verify our model and generate high-reliability code.”

Full case study here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy